Dr Samir Nuseibeh (UCL Biochemical Engineering) argues that the UK government could improve its negotiating position with the pharmaceutical industry by investing in facilities to manufacture a new class of “biological” drugs which are difficult to produce.
Read: The Conversation
Close
